{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:36:52Z","timestamp":1790498212869,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1245\/s10434-019-07513-6","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T17:02:44Z","timestamp":1560790964000},"page":"3561-3567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial"],"prefix":"10.1245","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6813-0616","authenticated-orcid":false,"given":"M.","family":"Bruzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Auclin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Lo Dico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Voron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Karoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Espin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Buggenhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Malafosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Denimal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Le Malicot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Vernerey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Douard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. F.","family":"Emile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Laurent-Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,17]]},"reference":[{"key":"7513_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin."},{"key":"7513_CR2","unstructured":"Lecomte T, Andre T, Fibeau F, et al. Cancer du c\u00f4lon non m\u00e9tastatique. Chapitre 3. Th\u00e9saurus Natl Canc\u00e9rologie Dig. \n                    www.tncd.org\/www.snfge.org\n                    \n                  . Accessed 21 Jan 2019."},{"key":"7513_CR3","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9 T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343\u201351.","journal-title":"N Engl J Med."},{"key":"7513_CR4","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1056\/NEJMoa043116","volume":"352","author":"C Twelves","year":"2005","unstructured":"Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696\u2013704.","journal-title":"N Engl J Med."},{"key":"7513_CR5","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdx030","volume":"28","author":"E Auclin","year":"2017","unstructured":"Auclin E, Zaanan A, Vernerey D, et al. Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. Ann Oncol. 2017;28:958\u201368.","journal-title":"Ann Oncol."},{"key":"7513_CR6","first-page":"88","volume":"148","author":"FA Sinicrope","year":"2015","unstructured":"Sinicrope FA, Shi Q, Smyrk TC, et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology. 2015;148:88\u201399.","journal-title":"Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated with Patient Outcomes."},{"key":"7513_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jamaoncol.2017.2899","volume":"4","author":"A Zaanan","year":"2018","unstructured":"Zaanan A, Shi Q, Taieb J, et al. Role of deficient DNA mismatch repair status in patients with stage III colon cancer treated with FOLFOX adjuvant chemotherapy a pooled analysis from 2 randomized clinical trials. JAMA Oncol. 2018;4:379\u201383.","journal-title":"JAMA Oncol."},{"key":"7513_CR8","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.5225","volume":"2","author":"J Taieb","year":"2016","unstructured":"Taieb J, Zaanan A, Le Malicot K, et al. Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab. JAMA Oncol. 2016;2:643\u201353.","journal-title":"JAMA Oncol."},{"key":"7513_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnci\/djw272","volume":"109","author":"J Taieb","year":"2017","unstructured":"Taieb J, Le Malicot K, Shi Q, et al. Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer. J Natl Cancer Inst. 2017;109:1\u201312.","journal-title":"J Natl Cancer Inst."},{"key":"7513_CR10","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1093\/annonc\/mdu464","volume":"25","author":"H Blons","year":"2014","unstructured":"Blons H, Emile JF, Le Malicot K, et al. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. Ann Oncol. 2014;25:2378\u201385.","journal-title":"Ann Oncol."},{"key":"7513_CR11","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/S1470-2045(14)70227-X","volume":"15","author":"J Taieb","year":"2014","unstructured":"Taieb J, Tabernero J, Mini E, et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:862\u201373.","journal-title":"Lancet Oncol."},{"key":"7513_CR12","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386\u2013422.","journal-title":"Ann Oncol."},{"key":"7513_CR13","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1080\/0284186X.2018.1487581","volume":"57","author":"T Prasanna","year":"2018","unstructured":"Prasanna T, Karapetis CS, Roder D, et al. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. Acta Oncol. 2018;57:1438\u201344.","journal-title":"Acta Oncol."},{"key":"7513_CR14","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1002\/cncr.26086","volume":"117","author":"B Tran","year":"2011","unstructured":"Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117:4623\u201332.","journal-title":"Cancer."},{"key":"7513_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.21873\/anticanres.11313","volume":"37","author":"K Fujiyoshi","year":"2017","unstructured":"Fujiyoshi K, Yamamoto G, Takenoya T, et al. Metastatic pattern of stage IV colorectal cancer with high-frequency microsatellite instability as a prognostic factor. Anticancer Res. 2017;37:239\u201347.","journal-title":"Anticancer Res."},{"key":"7513_CR16","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1001\/jamaoncol.2016.5469","volume":"3","author":"FA Sinicrope","year":"2017","unstructured":"Sinicrope FA, Shi Q, Allegra CJ, et al. Association of DNA mismatch repair and mutations in BRAF and KRAS with survival after recurrence in stage III colon cancers: a secondary analysis of 2 randomized clinical trials. JAMA Oncol. 2017;3:472\u201380.","journal-title":"JAMA Oncol."},{"key":"7513_CR17","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","volume":"20","author":"S Venderbosch","year":"2014","unstructured":"Venderbosch S, Nagtegaal ID, Maughan TS, et al. Mismatch repair\u00a0status\u00a0and BRAF mutation\u00a0status\u00a0in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20:5322\u201330.","journal-title":"Clin Cancer Res."},{"key":"7513_CR18","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1093\/annonc\/mdu100","volume":"25","author":"J Goldstein","year":"2014","unstructured":"Goldstein J, Tran B, Ensor J, et al. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol 2014;25:1032\u20138.","journal-title":"Ann Oncol"},{"key":"7513_CR19","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1158\/1078-0432.CCR-10-1720","volume":"17","author":"J Tie","year":"2011","unstructured":"Tie J, Lipton L, Desai J, et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res. 2011;17:1122\u201330.","journal-title":"Clin Cancer Res."},{"key":"7513_CR20","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/cam4.592","volume":"5","author":"M Ghidini","year":"2016","unstructured":"Ghidini M, Personeni N, Bozzarelli S, et al. KRAS mutation in lung metastases from colorectal cancer: prognostic implications. Cancer Med. 2016:5:256\u201364.","journal-title":"Cancer Med."},{"key":"7513_CR21","first-page":"645","volume":"6","author":"M Lipsyc","year":"2015","unstructured":"Lipsyc M, Yaeger R. Impact of somatic mutations on patterns of metastasis in colorectal cancer. J Gastrointest Oncol. 2015;6:645\u20139.","journal-title":"J Gastrointest Oncol."},{"key":"7513_CR22","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cncr.29196","volume":"121","author":"R Yaeger","year":"2015","unstructured":"Yaeger R, Cowell E, Chou JF, et al. RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer. 2015;121:1195\u2013203.","journal-title":"Cancer."},{"key":"7513_CR23","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/bjc.2011.19","volume":"104","author":"T Yokota","year":"2011","unstructured":"Yokota T, Ura T, Shibata N, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer. 2011;104:856\u201362.","journal-title":"Br J Cancer."},{"key":"7513_CR24","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1097\/PAS.0b013e31824430d7","volume":"36","author":"RK Pai","year":"2012","unstructured":"Pai RK, Jayachandran P, Koong AC, et al. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol. 2012;36:744\u201352.","journal-title":"Am J Surg Pathol."},{"key":"7513_CR25","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1002\/cncr.28599","volume":"120","author":"AL Russo","year":"2015","unstructured":"Russo AL, Borger DR, Szymonifka J, et al. Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer. 2015;120:1482\u201390.","journal-title":"Cancer."},{"key":"7513_CR26","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1002\/cncr.28729","volume":"120","author":"R Yaeger","year":"2014","unstructured":"Yaeger R. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer. 2014;120:2316\u201324.","journal-title":"Cancer."},{"key":"7513_CR27","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1078-0432.CCR-11-2246","volume":"18","author":"S Ogino","year":"2012","unstructured":"Ogino S, Shima K, Meyerhardt JA, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from Intergroup Trial CALGB 89803. Clin Cancer Res. 2012;18:890\u2013900.","journal-title":"Clin Cancer Res."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07513-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-019-07513-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07513-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T23:04:42Z","timestamp":1592262282000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-019-07513-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,17]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["7513"],"URL":"https:\/\/doi.org\/10.1245\/s10434-019-07513-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,17]]},"assertion":[{"value":"2 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}